Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib + siremadlin in myelofibrosis
CTR20220778Phase 2Terminated
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of siremadlin in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Novartis. Primary endpoint: Preliminary efficacy of ruxolitinib-based novel combination (Parts 2 and 3). Started Apr 2022; status: terminated.
02
Drugs
siremadlin
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on CTR20220778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220778.